PTK787/ZK 222584

Phase 2Small molecule

Novartis

PTK787/ZK 222584 is one of 144 small molecule programs targeting Hemangioblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

143

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemangioblastomaActive, not recruiting

Malignant MesotheliomaActive, not recruiting

MelanomaActive, not recruiting

GlioblastomaActive, not recruiting

Multiple MyelomaActive, not recruiting

HemangioblastomaPhase 2

Active, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

PTK787/ZK 222584

Novartis

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Abecma

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malignant Mesothelioma1 trial

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053885·47 enrolled

Melanoma1 trial

PTK/ZK in Disseminated Malignant Melanoma

Terminated·MMichael Weichenthal·Phase 1/2·NCT00615160·9 enrolled

Multiple Myeloma1 trial

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 2·NCT00240162·21 enrolled

Glioblastoma1 trial

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

Completed·MMassachusetts General Hospital·Phase 1·NCT00385853·19 enrolled

Paclitaxel1 trial

Trial of PTK787/ZK 222584 Plus Paclitaxel

Terminated·—·Phase 1·NCT00358163·7 enrolled

2 more indications

Hemangioblastoma1 trial

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Completed· Novartis logo

Novartis·Phase 2·NCT00052013·11 enrolled

Advanced Cancer1 trial

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

Completed· Novartis logo

Novartis·Phase 1/2·NCT00171587·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PTK787/ZK 222584. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTK787/ZK 222584 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTK787/ZK 222584. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

PTK787/ZK 222584

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malignant Mesothelioma1 trial

Melanoma1 trial

Multiple Myeloma1 trial

Glioblastoma1 trial

Paclitaxel1 trial

Hemangioblastoma1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News